Modality
siRNA
MOA
GLP-1/GIP
Target
CDK4/6
Pathway
Neuroinflam
UCDMD
Development Pipeline
Preclinical
~Dec 2022
→ ~Mar 2024
Phase 1
~Jun 2024
→ ~Sep 2025
Phase 2
Dec 2025
→ Apr 2030
Phase 2Current
NCT06681745
2,189 pts·UC
2025-12→2030-04·Active
2,189 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-04-094.0y awayPh2 Data· UC
Trial Timeline
2026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
P2
Active
Catalysts
Ph2 Data
2030-04-09 · 4.0y away
UC
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06681745 | Phase 2 | UC | Active | 2189 | VA |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Johnson & Johnson | Phase 2/3 | TIGIT | |
| JNJ-8168 | Johnson & Johnson | Phase 2/3 | FLT3 | |
| AZN-5171 | AstraZeneca | Approved | GLP-1R | |
| Motavorutinib | Amgen | Phase 3 | CDK4/6 | |
| Ribozanubrutinib | Regeneron | Phase 1 | CDK4/6 | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| Pemiinavolisib | Sarepta | NDA/BLA | CD47 | |
| Elralucimab | Axsome | Phase 2 | CDK4/6 | |
| BEA-4274 | Beam | Phase 1/2 | ALK | |
| Rimanaritide | Agios | Phase 1 | CDK4/6 |